CGTX – cognition therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics (NASDAQ:CGTX) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine's Potential to Slow the Progression of Dementia with Lewy Bodies [Yahoo! Finance]
Form 4 COGNITION THERAPEUTICS For: Feb 03 Filed by: Ricciardi Lisa
Form 4 COGNITION THERAPEUTICS For: Feb 03 Filed by: Doyle John Brendan
Form 4 COGNITION THERAPEUTICS For: Feb 03 Filed by: Caggiano Anthony
Form 8-K COGNITION THERAPEUTICS For: Jan 27
Form EFFECT COGNITION THERAPEUTICS
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.